New Obesity Drug Lorcaserin Passes Major Safety Tests

The new obesity drug lorcaserin is in Phase 3 (final stage) trials, which are double-blind, randomized, drug trials with 3,200 patients in 100 centers in the United States. Echocardiograms were done to make sure that the new drug had no adverse effects on heart valves and so far it looks safe. Locaserin is the first in a new class of obesity drugs that target the 5-HT2C serotonin receptor, located in the hypothalamus, which regulates food intake and metabolism. The results from the Phase 2 studies showed that lorcaserin produced highly statistically significant, progressive weight loss over a 12-weeks. Lorcaserin was well tolerated at all doses in the Phase 2 drug trials and had no apparent effects on the heart valves or on the pulmonary artery pressure.

Read about it HERE


http://healthblaster.com/?p=42

Frequency Of Meals Can Affect Health

A recent government sponsored study results showed that eating a one-meal-per-day diet, rather than a more normal three-meal-per-day diet, is possible for a short duration. It showed that when the participants were one-mealers, they experienced negative effects such as increases in total cholesterol, LDL "bad" cholesterol and in their blood pressure, as compared to when they were three-mealers.

Read more HERE

More Obesity and Medical News is HERE

Gene Regulation Affects Onset Of Obesity and Other Diseases

Epigenetics which refers to gene expression and regulation is a rapidly advancing science. A new study of obese patients in Iceland has offered new insights as to how some genes are regulated and associated.Gene variations create either increased or decreased chances of developing obesity or type II diabetes by regulating the activity of major biochemical pathways. The result is that gene variants determine an individuals risk of developing these problems. Most of the population has roughly average risk and smaller numbers of people have either much higher or lower risk.

http://healthblaster.com/?p=43